Page last updated: 2024-08-25

rosiglitazone and Jaundice, Cholestatic

rosiglitazone has been researched along with Jaundice, Cholestatic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ao, JP; Li, HH; Li, YS; Lv, X; Song, JG; Song, SL; Wang, XR; Zhang, P	1

Other Studies

1 other study(ies) available for rosiglitazone and Jaundice, Cholestatic

Article	Year
Decreased hepatic peroxisome proliferator-activated receptor-γ contributes to increased sensitivity to endotoxin in obstructive jaundice. World journal of gastroenterology, 2011, Dec-28, Volume: 17, Issue:48 Topics: Alanine Transaminase; Animals; Bile Ducts; Cholestasis; Endotoxemia; Endotoxins; Hypoglycemic Agents; Interleukin-1; Interleukin-6; Jaundice, Obstructive; Ligation; Liver; Male; Peroxisomes; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Survival Rate; Thiazolidinediones; Tumor Necrosis Factor-alpha	2011

Article

Year

Decreased hepatic peroxisome proliferator-activated receptor-γ contributes to increased sensitivity to endotoxin in obstructive jaundice.

World journal of gastroenterology, 2011, Dec-28, Volume: 17, Issue:48

Topics: Alanine Transaminase; Animals; Bile Ducts; Cholestasis; Endotoxemia; Endotoxins; Hypoglycemic Agents; Interleukin-1; Interleukin-6; Jaundice, Obstructive; Ligation; Liver; Male; Peroxisomes; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Survival Rate; Thiazolidinediones; Tumor Necrosis Factor-alpha

2011